RT Journal Article
SR Electronic
T1 COVID-19 associated autoimmunity is a feature of severe respiratory disease - a Bayesian analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251953
DO 10.1101/2021.02.17.21251953
A1 Uriel Trahtemberg
A1 Robert Rottapel
A1 Claudia C dos Santos
A1 Alex P Di Battista
A1 Arthur S. Slutsky
A1 Andrew J Baker
A1 Marvin J Fritzler
A1 on behalf of the COVID19 Longitudinal Biomarkers of Lung Injury (COLOBILI) study group
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251953.abstract
AB Background Serological and clinical features with similarities to systemic autoimmunity have been reported in severe COVID-19, but there is a lack of studies that include contemporaneous controls who do not have COVID-19.Methods Observational cohort study of adult patients admitted to an intensive care unit with acute respiratory failure. Patients were divided into COVID+ and COVID− based on SARS-CoV-2 PCR from nasopharyngeal swabs and/or endotracheal aspirates. No COVID-19 specific interventions were given. The primary clinical outcome was death in the ICU within 3 months; secondary outcomes included in-hospital death and disease severity measures. Measurements including autoantibodies, were done longitudinally. ANOVA and Fisher’s exact test were used with α=0.05, with a false discovery rate of q=0.05. Bayesian analysis was performed to provide credible estimates of the possible states of nature compatible with our results.Results 22 COVID+ and 20 COVID− patients were recruited, 69% males, median age 60.5 years. Overall, 64% had anti-nuclear antibodies, 38% had antigen-specific autoantibodies, 31% had myositis related autoantibodies, and 38% had high levels of anti-cytokine autoantibodies. There were no statistically significant differences between COVID+ and COVID− for any of the clinical or autoantibody parameters. A specific pattern of anti-nuclear antibodies was associated with worse clinical severity for both cohorts.Conclusions Severe COVID+ patients have similar humoral autoimmune features as comparably ill COVID− patients, suggesting that autoantibodies are a feature of critical illness regardless of COVID-19 status. The clinical significance of autoimmune serology and the correlation with severity in critical illness remains to be elucidated.Competing Interest StatementMJF is the Director of MitogenDx. MJF is a consultant for and received speaking honoraria from Inova Diagnostics Inc (San Diego, CA) and Werfen International (Barcelona, Spain). All the other authors have no disclosures to declare.Clinical TrialNCT04747782Funding Statement- St Michael's Hospital Foundation, internal competitive grant to AB and CDS. - Autoantibody testing was provided as a gift in kind by MitogenDx (Calgary, AB, Canada) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by Research Ethics Boards at St Michael's Hospital and performed in accordance with the Helsinki Declaration of 1975 as revised in 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.